Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics director Samantha Truex received a new stock option grant, not an open-market share purchase. She was granted options to buy 20,100 shares of Avalo Therapeutics common stock at an exercise price of $13.96 per share. These options vest 100% on the first anniversary of the grant date, contingent on her continued board service, and expire on June 2, 2036. Following this award, she holds 20,100 stock options directly, with no sales or exercises reported in this filing.
Avalo Therapeutics, Inc. director Gilla Kaplan received a grant of stock options linked to the company’s common stock. The award covers 20,100 options with an exercise price of $13.96 per share and expires on June 2, 2036.
According to the terms, the option vests 100% on the first anniversary of the grant date, as long as the director continues to serve through that date. After this grant, Kaplan holds 20,100 stock options directly, giving equity-based, long-term incentive aligned with future company performance.
Avalo Therapeutics director Aaron Kantoff received a new stock option grant as part of his compensation. On the grant date, he was awarded options covering 20,100 shares of Avalo Therapeutics common stock at an exercise price of $13.96 per share. These options vest 100% on the first anniversary of the grant date, as long as he continues serving as a director on that date, and expire on June 2, 2036. After this grant, his total reported stock option holdings from this award are 20,100 options, with no open-market buying or selling involved.
Avalo Therapeutics, Inc. director Michael Thomas Heffernan received a grant of stock options as compensation. He was awarded 29,500 stock options, each giving the right to buy common stock at an exercise price of $13.96 per share. The options vest 100% on the first anniversary of the grant date, provided he continues to serve as a director on that vesting date. After this grant, he holds 29,500 stock options directly, and the options are scheduled to expire on June 2, 2036.
Avalo Therapeutics director Rita Jain received a new stock option grant. The award covers 20,100 options to buy Avalo Therapeutics common stock at an exercise price of $13.96 per share, with all options vesting 100% on the first anniversary of the grant date, subject to her continued board service.
Following this compensation-related grant, Jain holds 20,100 stock options directly, and the options are scheduled to expire on June 2, 2036. The filing does not show any open‑market purchases or sales of Avalo Therapeutics shares, only this option award.
AVTX affiliate filed a Form 144 to report proposed sales and issuances of Common Stock related to option exercises and restricted stock vesting. The notice lists proposed sales or issuances on 06/02/2026, including 16,400, 3,166, 3,167 and 20,100 shares tied to exercises and vesting under registered plans.
The filing names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and indicates cash transactions for option exercises; additional procedural details and whether shares have already been sold are not shown in the excerpt.
Avalo Therapeutics, Inc.’s Chief Medical Officer, Doyle Mittie, reported an exercise-and-sell stock transaction. On May 28, 2026, she exercised stock options to acquire 679 shares of common stock at $8.04 per share and sold 679 shares in an open-market trade at $16.00 per share.
The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025. Following these trades, she directly holds 47,122 shares of common stock and 118,321 stock options that remain outstanding.
Avalo Therapeutics, Inc. Schedule 13G: Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report beneficial ownership of 3,055,027 shares of Avalo Common Stock, representing 5.81% of the class as reported.
The filing states the ownership figures are calculated using 52,565,572 shares outstanding as of May 8, 2026, per the issuer's 10-Q. The statement is a joint filing by the named reporting persons and identifies Deep Track Capital, LP as the relevant entity for which Kroin may be considered a control person.
Point72 Asset Management and affiliates reported beneficial ownership of 2,710,817 shares of Avalo Therapeutics common stock, representing 5.2% of the class as of the close of business on May 22, 2026. The filing states Point72 Asset Management and Point72 Capital Advisors have shared voting and dispositive power over these shares through holdings of Point72 Associates, and that Steven A. Cohen controls the reporting entities. The statement is filed as a joint Schedule 13G under Rule 13d-1(k) and is accompanied by a Joint Filing Agreement (Exhibit 99.1).
Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported an acquisition of 34,200 shares of Common Stock on May 21, 2026, at a stated price of $0.00 per share. After this award, she directly holds 36,855 shares.
According to the footnote, this represents performance stock units granted on August 19, 2025. Each unit is a contingent right to one share, tied to performance goals that the Compensation Committee certified on May 21, 2026. The shares are scheduled to fully vest on August 19, 2028, assuming her continued service.